A PYMNTS Company

France: French pharmaceuticals group proposes US merger

By  |  March 3, 2015

Stallergenes’ controlling shareholder proposed merging the French pharmaceuticals group’s operations with its U.S. partner Greer to create a specialist in allergy immunotherapy with combined sales of 330 million euros.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “Ares Life Sciences’ proposal gives us a tremendous opportunity to reinforce our relationship with Greer,” said Stallergenes Chief Executive Christian Chavy said.

     

    Full Content: Reuters

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.